Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Argenx Prepares FDA Filing to Expand Vyvgart Use in Myasthenia Gravis After Late-Stage Trial Win
Argenx; Vyvgart; FDA approval; myasthenia gravis; prefilled syringe; self-injection; chronic inflammatory demyelinating polyneuropathy; generalized myasthenia gravis; clinical trial
Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis
Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment
Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio
Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.
Argenx’s Vyvgart Hytrulo Secures Second US Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Vyvgart Hytrulo, Argenx, FDA Approval, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Disease, Peripheral Nervous System Disorder